Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction

Sildenafil citrate is marketed under the trademark name Viagra® and is widely used to treat male erectile dysfunction; therapeutic uses of this medication for other diseases related to vascular dysfunction are emerging. When used as recommended, the drug has a strong clinical efficacy and safety profile in a broad spectrum of the male population. Its widespread use and effects of long-term exposure to the drug due to particular treatment regimens or inappropriate use mandate an ongoing update of its molecular mechanism, pharmacological profile and associated safety issues. This review focuses on biochemical and pharmacological features of sildenafil, the active component in Viagra, interaction of sildenafil with phosphodiesterase 5, pharmacokinetic parameters, action in smooth muscle, side effects, safety profile and prospects for other uses.

[1]  M. Rizzo,et al.  Heavy smoking is an important risk factor for erectile dysfunction in young men , 2005, International Journal of Impotence Research.

[2]  A. Hatzelmann,et al.  The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. , 2005, Cellular signalling.

[3]  R. Roberts,et al.  Association between smoking and erectile dysfunction: a population-based study. , 2005, American journal of epidemiology.

[4]  V. Fonseca,et al.  Erectile dysfunction: Interrelationship with the metabolic syndrome , 2005, Current diabetes reports.

[5]  M. Sofer,et al.  Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? , 2005, The Journal of urology.

[6]  F. Hofmann.  The Biology of Cyclic GMP-dependent Protein Kinases* , 2005, Journal of Biological Chemistry.

[7]  R. Crosby,et al.  A Descriptive Analysis of HIV Risk Behavior Among Men Having Sex With Men Attending a Large Sex Resort , 2004, Journal of acquired immune deficiency syndromes.

[8]  G. Mancia,et al.  Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. , 2004, American journal of hypertension.

[9]  H. Özkardeş,et al.  Sublingual sildenafil in the treatment of erectile dysfunction: Faster onset of action with less dose , 2004, International journal of urology : official journal of the Japanese Urological Association.

[10]  C. Carson.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease , 2004 .

[11]  F. Hofmann,et al.  IRAG is essential for relaxation of receptor‐triggered smooth muscle contraction by cGMP kinase , 2004, The EMBO journal.

[12]  J. V. Samsó,et al.  Specific aspects of erectile dysfunction in spinal cord injury , 2004, International Journal of Impotence Research.

[13]  J. Jara,et al.  Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. , 2004, European urology.

[14]  A. Burnett.  The impact of sildenafil on molecular science and sexual health. , 2004, European urology.

[15]  R. Zoraghi,et al.  Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. , 2004, Molecular pharmacology.

[16]  R. Marfella,et al.  Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. , 2004, JAMA.

[17]  H. Son,et al.  Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. , 2004, Asian journal of andrology.

[18]  R. Swindle,et al.  The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. , 2004, The Journal of urology.

[19]  C. Foresta,et al.  Role of androgens in erectile function. , 2004, The Journal of urology.

[20]  S. Archer,et al.  Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. , 2004, Archives of internal medicine.

[21]  C. Pepine,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease , 2004, The American journal of cardiology.

[22]  J. Corbin,et al.  Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists , 2003, Current urology reports.

[23]  S. Rosenkranz,et al.  Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. , 2003, Annals of internal medicine.

[24]  J. Corbin,et al.  Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. , 2003, Journal of andrology.

[25]  F. Hofmann,et al.  Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3′,5′-Cyclic Monophosphate–Dependent Protein Kinase , 2003 .

[26]  S. Archer,et al.  Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.

[27]  T. Roumeguère,et al.  Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. , 2003, European urology.

[28]  J. Orazem,et al.  Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. , 2003, Urology.

[29]  B. Trock,et al.  Clinical efficacy of sildenafil citrate and predictors of long-term response. , 2003, The Journal of urology.

[30]  M. Böhm,et al.  Non Erectile Dysfunction Application of Sildenafil , 2003, Herz.

[31]  F. Hofmann,et al.  Direct activation of PDE5 by cGMP , 2003, The Journal of cell biology.

[32]  F. Montorsi,et al.  Pharmacological management of erectile dysfunction , 2003, BJU international.

[33]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[34]  S. Carrier.  Pharmacology of phosphodiesterase 5 inhibitors. , 2003, The Canadian journal of urology.

[35]  F. Montorsi,et al.  Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. , 2003, Diabetes care.

[36]  F. Montorsi,et al.  Sildenafil in erectile dysfunction: a critical review , 2003, Current medical research and opinion.

[37]  C. Çavdar,et al.  Sexual dysfunction in male patients on hemodialysis: assessment with the International Index of Erectile Function (IIEF) , 2002, International Journal of Impotence Research.

[38]  M. Chopp,et al.  Sildenafil (Viagra) Induces Neurogenesis and Promotes Functional Recovery After Stroke in Rats , 2002, Stroke.

[39]  A. Quyyumi,et al.  The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. , 2002, Journal of the American College of Cardiology.

[40]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[41]  David P. Rotella,et al.  Phosphodiesterase 5 inhibitors: current status and potential applications , 2002, Nature Reviews Drug Discovery.

[42]  A. Atz,et al.  Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. , 2002, The Journal of thoracic and cardiovascular surgery.

[43]  J. Urquhart,et al.  Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users , 2002, International Journal of Impotence Research.

[44]  M. Fava,et al.  Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. , 2002, Urology.

[45]  F. Montorsi,et al.  A 4-year update on the safety of sildenafil citrate (Viagra). , 2002, Urology.

[46]  A. Burnett,et al.  The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. , 2002, Urology.

[47]  J. Corbin,et al.  PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS , 2002, International journal of clinical practice.

[48]  E. Sprecher,et al.  Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. , 2002, Urology.

[49]  P. Lim,et al.  The Clinical Safety of Viagra , 2002, Annals of the New York Academy of Sciences.

[50]  F. Montorsi,et al.  The ageing male and erectile dysfunction , 2002, World Journal of Urology.

[51]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[52]  G. Muirhead,et al.  Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. , 2002, British journal of clinical pharmacology.

[53]  K. Wilner,et al.  The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. , 2002, British journal of clinical pharmacology.

[54]  G. Muirhead,et al.  The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. , 2002, British journal of clinical pharmacology.

[55]  K. Wilner,et al.  The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. , 2002, British journal of clinical pharmacology.

[56]  I. Eardley,et al.  Onset and duration of action of sildenafil for the treatment of erectile dysfunction. , 2002, British journal of clinical pharmacology.

[57]  D. Walker,et al.  Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. , 2002, British journal of clinical pharmacology.

[58]  F. Montorsi,et al.  Counselling the patient with prostate cancer about treatment-related erectile dysfunction , 2001, Current opinion in urology.

[59]  R. Newton,et al.  Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. , 2001, Journal of andrology.

[60]  T. Lincoln,et al.  Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. , 2001, Journal of applied physiology.

[61]  R. Shabsigh,et al.  Efficacy, safety, and use of sildenafil in urologic practice. , 2001, Urology.

[62]  J. Corbin,et al.  Allosteric sites of phosphodiesterase-5 (PDE5) , 2001 .

[63]  W. Klaus,et al.  Modulation of Human Platelet Aggregation by the Phosphodiesterase Type 5 Inhibitor Sildenafil , 2001, Journal of cardiovascular pharmacology.

[64]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. , 2001, British journal of clinical pharmacology.

[65]  G. Hackett,et al.  THREE‐YEAR UPDATE OF SILDENAFIL CITRATE (VIAGRA®) EFFICACY AND SAFETY , 2001, International journal of clinical practice.

[66]  F. Montorsi,et al.  Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[67]  Morris J. Brown,et al.  Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication , 2000 .

[68]  H A Feldman,et al.  Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? , 2000, Urology.

[69]  G. Muirhead,et al.  Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. , 2000, British journal of clinical pharmacology.

[70]  D. Webb,et al.  Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. , 2000, Journal of the American College of Cardiology.

[71]  C. Stief,et al.  Gene Expression of the Phosphodiesterases 3A and 5A in Human Corpus cavernosum Penis , 2000, European Urology.

[72]  H. Herrmann,et al.  Hemodynamic effects of sildenafil in men with severe coronary artery disease. , 2000, The New England journal of medicine.

[73]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[74]  D. Greenblatt,et al.  In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[75]  T. Lue,et al.  Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. , 2000, Biochemical and biophysical research communications.

[76]  M. Bortolotti,et al.  Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. , 2000, Gastroenterology.

[77]  J. Corbin,et al.  Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* , 1999, The Journal of Biological Chemistry.

[78]  J. Corbin,et al.  Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. , 1999, Critical reviews in clinical laboratory sciences.

[79]  I. Eardley,et al.  Sildenafil citrate (VIAGRA): an oral treatment for erectile function with activity for up to four hours' duration. , 1999, International journal of clinical practice. Supplement.

[80]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[81]  L. Highleyman.  Protease inhibitors and sildenafil (Viagra) should not be combined. , 1999, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[82]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[83]  C. Conti,et al.  Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. , 1999, The American journal of cardiology.

[84]  I. Osterloh,et al.  Overall cardiovascular profile of sildenafil citrate. , 1999, The American journal of cardiology.

[85]  G. Jackson,et al.  Effects of sildenafil citrate on human hemodynamics. , 1999, The American journal of cardiology.

[86]  J. Rajfer,et al.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. , 1999, JAMA.

[87]  S. Ballard,et al.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. , 1998, The Journal of urology.

[88]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[89]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[90]  J. Corbin,et al.  Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. , 1990, The Journal of biological chemistry.

[91]  R. Haslam,et al.  Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. , 1990, Molecular pharmacology.

[92]  A. L. A S T A I,et al.  Erectile dysfunction. , 2006, Harvard men's health watch.

[93]  T. H. Klotz,et al.  Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? , 2005, International Journal of Impotence Research.

[94]  S. Madersbacher,et al.  Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. , 2005, European urology.

[95]  U. Engelmann,et al.  Future Options for Combination Therapy in the Management of Erectile Dysfunction in Older Men , 2004, Drugs & aging.

[96]  J. W. Park,et al.  Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric, prospective, double-blind, placebo-controlled, randomized cross-over study. , 2004, Clinical hemorheology and microcirculation.

[97]  U. Walter,et al.  Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase. , 2004, Acta biochimica Polonica.

[98]  F. Hofmann,et al.  Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. , 2003, Circulation.

[99]  D. Price,et al.  Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[100]  S. Archer,et al.  The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. , 2003, Advances in experimental medicine and biology.

[101]  R. Kloner,et al.  Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. , 2001, American journal of hypertension.

[102]  J. Corbin,et al.  Cyclic nucleotide phosphodiesterases: relating structure and function. , 2001, Progress in nucleic acid research and molecular biology.

[103]  J. Corbin,et al.  Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. , 2001, European journal of biochemistry.

[104]  T. Tensfeldt,et al.  Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. , 2000, British journal of clinical pharmacology.

[105]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[106]  P. Wright,et al.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[107]  A. Laties,et al.  Ocular safety of Viagra, (sildenafil citrate). , 1999, Transactions of the American Ophthalmological Society.

[108]  H A Feldman,et al.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. , 1994, The Journal of urology.

[109]  J. Raymond.  [Cyclic AMP]. , 1972, La Nouvelle presse medicale.